NASDAQ | DRNA

$2.79 + 0.06 (+2.198%)

3 month stock price graph

3:59 PM ET on Feb 24, 2017 Pricing delayed 20 minutes

Investors & Media

Press Releases

 
Press Releases
  Date Title and Summary View
Feb 8, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat at the Leerink Par...
Feb 2, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 31, 2017, the Compensation Committee of the Company's Board of Directors approved the grant of an inducement stock ...
Nov 9, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2016 Healthcare Conference on Wednesday,...
Nov 7, 2016
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the third quarter ended...
Oct 31, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2016 financial results after market close on Monday, November 7, 2016. ...
Sep 26, 2016
Primary Hyperoxaluria Development Program Transitioned From DCR-PH1 to Subcutaneously Delivered GalXC Candidate DCR-PHXC Clinical Development Discontinued for DCR-MYC in Oncology Indications CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DR...
Sep 6, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following investor conferences in September. ...
Aug 4, 2016
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the second quarter ende...
Jul 28, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2016 financial results after market close on Thursday, August 4, 2016. ...
Jun 29, 2016
Consistent, Potent and Durable Silencing of Multiple Disease-Driving Genes in Non-Human Primates Reported at Investor Day Initial GalXC Program on Track for First IND Filing in Late 2017 Live Webcast to Begin at 8:30 a.m. Eastern Time CAMBRIDGE, Mass.--(BUSINE...
Page:
1
... NextLast
= add release to Briefcase